Table 2 Quantitative interferon-γ (IFN-γ) responses to anti-CD3 (positive control) and mycobacterial antigens as assessed by ELISPOT assay and 7-day whole blood assay (WBA)
Patient characteristics | ELISPOTa | WBAb | ||||||
|---|---|---|---|---|---|---|---|---|
Anti-CD3 | PPD | ESAT-6 | CFP-10 | PHA | PPD | ESAT-6 | CFP-10 | |
HIV- (n = 30) | 1723 (846–2471) | 61 (26–214) | 24 (7–199) | 30 (6–89) | >10,000 | >10,000 | 4820 | 3678 |
HIV+ (n = 40) | 626 (398–2015) | 21 (2–53) | 7 (2–46) | 6 (0–39) | 3991 | 799 | 355 | 96 |
P value | 0.012 | 0.001 | 0.004 | 0.010 | <0.001 | <0.001 | <0.001 | <0.001 |
HIV+ CD4>100 c (n = 23) | 654 (290–2296) | 30 (4–64) | 16 (2–58) | 30 (0–82) | 4213 | 616 | 34 | 49 |
HIV+ CD4<100 (n = 17) | 600 (400–1912) | 8 (2–49) | 2 (1–17) | 1 (1–10) | 2550 | 1034 | 528 | 125 |
P value | 0.93 | 0.42 | 0.19 | 0.12 | 0.13 | 0.89 | 0.14 | 0.12 |
HIV+ no previous TB Rx d (n = 19) | 476 (269–2299) | 34 (3–147) | 22 (2–80) | 36 (1–80) | 6938 | 1529 | 495 | 179 |
HIV+ previous TB Rx (n = 21) | 1020 (400–1844) | 6 (2–42) | 5 (0–14) | 0 (0–6) | 2749 | 313 | 65 | 20 |
P value | 0.70 | 0.085 | 0.044 | 0.028 | 0.10 | 0.115 | 0.220 | 0.038 |